Literature DB >> 14508857

Surgery for early stage non-small cell lung cancer.

Michael Y Chang1, David J Sugarbaker.   

Abstract

Lung cancer accounts for 28.2% of all cancer-related deaths in the United States. Most patients present with advanced-stage disease, with only 15% having disease confined to the lung. Surgical resection is the optimal treatment for Stage I and II non-small cell lung cancer. Pre-resection staging includes various radiographic modalities, including PET scan and mediastinoscopy. Survival and local recurrence statistics favor full anatomic lobar resection over sublobar resection, although cases must be judged individually. Lobectomy via thoracoscopic approach appears to have equivalent outcome as lobectomy via thoracotomy. Characteristics of the counseling physician and the hospital volume at which the surgery is performed can also influence outcome. After surgical resection, stage IA patients have about 70% 5-year survival, but this falls below 50% for stage IIB patients. Methods that identify early-stage lung cancer patients at greatest risk for recurrence are needed to identify patients who may benefit from additional therapies. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 14508857     DOI: 10.1002/ssu.10024

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  12 in total

1.  A method for improved verification of entire IMRT plans by film dosimetry.

Authors:  Vesna Jacob; Peter Kneschaurek
Journal:  Strahlenther Onkol       Date:  2009-02-18       Impact factor: 3.621

2.  Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC.

Authors:  S Arcangeli; L Agolli; L Portalone; M R Migliorino; M G Lopergolo; A Monaco; J Dognini; M C Pressello; S Bracci; V Donato
Journal:  Br J Radiol       Date:  2015-02-03       Impact factor: 3.039

3.  Differential response to ablative ionizing radiation in genetically distinct non-small cell lung cancer cells.

Authors:  Ayman Oweida; Zeinab Sharifi; Hani Halabi; Yaoxian Xu; Siham Sabri; Bassam Abdulkarim
Journal:  Cancer Biol Ther       Date:  2016-04-02       Impact factor: 4.742

4.  Influenza infection induces host DNA damage and dynamic DNA damage responses during tissue regeneration.

Authors:  Na Li; Marcus Parrish; Tze Khee Chan; Lu Yin; Prashant Rai; Yamada Yoshiyuki; Nona Abolhassani; Kong Bing Tan; Orsolya Kiraly; Vincent T K Chow; Bevin P Engelward
Journal:  Cell Mol Life Sci       Date:  2015-03-26       Impact factor: 9.261

5.  Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma.

Authors:  Lynette M Sholl; Justine A Barletta; Beow Y Yeap; Lucian R Chirieac; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

6.  Racial composition of hospitals: effects on surgery for early-stage non-small-cell lung cancer.

Authors:  Christopher S Lathan; Bridget A Neville; Craig C Earle
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

7.  Surgery in high-volume hospitals not commission on cancer accreditation leads to increased cancer-specific survival for early-stage lung cancer.

Authors:  Elizabeth A David; David T Cooke; Yingjia Chen; Andrew Perry; Robert J Canter; Rosemary Cress
Journal:  Am J Surg       Date:  2015-06-27       Impact factor: 3.125

8.  Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer.

Authors:  Min-Jeong Kim; Seung-Gu Yeo; Eun Seok Kim; Chul Kee Min; Pyung Se An
Journal:  Oncol Lett       Date:  2012-12-18       Impact factor: 2.967

9.  Immune responses following stereotactic body radiotherapy for stage I primary lung cancer.

Authors:  Yoshiyasu Maehata; Hiroshi Onishi; Kengo Kuriyama; Shinichi Aoki; Masayuki Araya; Ryo Saito; Licht Tominaga; Mitsuhiko Oguri; Tsutomu Araki
Journal:  Biomed Res Int       Date:  2013-11-10       Impact factor: 3.411

10.  SBRT Treatment of Metachronous Small-Cell and Non-Small-Cell Lung Carcinomas in a Patient with Severe COPD.

Authors:  Adele Duimering; Zsolt Gabos; Brock Debenham
Journal:  Cureus       Date:  2015-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.